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110Objectives:A new class of rapid-deployment aortic valves has emerged with the potential to simplify minimally
invasive aortic surgery and reduce crossclamp and cardiopulmonary bypass times. We report the 1-year clinical
outcomes of aortic valve replacement with the EDWARDS INTUITY Valve System (Edwards Lifesciences
LLC, Irvine, Calif) in the Surgical Treatment of Aortic Stenosis With a Next Generation Surgical Aortic Valve
(TRITON) trial.
Methods: Seventeen surgeons from 6 European centers treated 152 consecutive patients with aortic stenosis re-
quiring valve replacement in a prospective, single-arm trial. A stented trileaflet bovine pericardial bioprosthesis
with a balloon-expandable, cloth-covered stent frame at the inflow aspect was implanted in 146 patients (mean
age, 75.5  6.7 years; 52.7% were female). Five valve sizes were evaluated (19-27 mm); 58.9% of cases had
isolated aortic valve replacement, and 41.1% of cases involved concomitant procedures. Minimally invasive
surgical approaches occurred in 48.8% of the isolated aortic valve replacements. Patients were followed at dis-
charge, 3 months, and 1 year postoperatively.
Results: Implantation success was 96.1% (146/152), early valve-related mortality was 1.4% (2/146), and
cumulative survival was 92.5% at a mean follow-up of 9.8  5.1 months. Crossclamp time for isolated aortic
valve replacement was 41.1  10.6 minutes. Independent core laboratory–adjudicated mean effective orifice
area and aortic valve pressure gradient were 1.7  0.2 cm2 and 8.8  3.0 mm Hg at 3 months, and 1.7  0.2
cm2 and 8.4  3.4 mm Hg at 1 year, respectively.
Conclusions: Implantation of the EDWARDS INTUITY Valve System is feasible, safe, and efficacious for aor-
tic valve replacement. Aortic crossclamp and cardiopulmonary bypass times were reduced compared with those
for conventional aortic valve replacement. Early hemodynamic performance was excellent and remained so up
to 1 year. (J Thorac Cardiovasc Surg 2013;145:110-6)Surgical aortic valve replacement (AVR) with cardiopulmo-
nary bypass (CPB) has been the treatment of choice for
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The Journal of Thoracic and Cardiovascular Surgadvances in valve technology have led to considerable im-
provements in both valve design and surgical implant tech-
nique of aortic bioprostheses. Enhanced structural design
modifications to achieve increased effective orifice area
(EOA) and reduced strut height have led to superior hemo-
dynamics.1-4 Moreover, advancements in aortic valve
design have facilitated minimally invasive surgical
approaches while achieving reductions in procedural
times.5 Although transcatheter AVR has expanded the treat-
ment options for aortic stenosis, this therapy is currently
reserved for patients who are ineligible for traditional
AVR surgical approaches because of advanced age, poor
left ventricular systolic function, severe comorbidities,
and high-risk anatomic characteristics.6,7
A novel rapid-deployment AVR (RDAVR) technique has
recently been introduced for conventional AVR in patients
with aortic stenosis. The EDWARDS INTUITY Valveery c January 2013
Abbreviations and Acronyms
AVR ¼ aortic valve replacement
CABG ¼ coronary artery bypass grafting
CPB ¼ cardiopulmonary bypass
EOA ¼ effective orifice area
NYHA ¼ New York Heart Association
RDAVR ¼ rapid-deployment aortic valve
replacement
TRITON ¼ Surgical Treatment of Aortic Stenosis
With a Next Generation Surgical Aortic
Valve trial
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DSystem (Edwards Lifesciences LLC, Irvine, Calif) is
designed for RDAVR and is built on the proven long-term
safety and efficacy of the Carpentier-Edwards Perimount
(Edwards Lifesciences LLC) family of valves while
leveraging recent design innovation from Edwards’ trans-
catheter heart valves. The EDWARDS INTUITY Valve
System consists of a bioprosthesis, delivery system, and
balloon catheter, which is used to deploy the valve after
placement within the aortic annulus. Clinical benefits of
RDAVR may include reduced operative times, decreased
morbidity, faster recovery, and less-invasive surgical
options for patients undergoing valve replacement.8,9
The current study presents the 1-year clinical outcomes
and device efficacy of the first 146 subjects receiving an
EDWARDS INTUITY Valve in a prospective, multicenter
study (Surgical Treatment of Aortic Stenosis With
a Next Generation Surgical Aortic Valve [TRITON],
ClinicalTrials.gov number, NCT01445171). The purpose of
the TRITON trial was to evaluate the safety, feasibility, and
efficacy of the EDWARDS INTUITY Valve System.METHODS AND MATERIALS
Study Population
Seventeen surgeons from 6 European centers treated 152 consecutive
patients with aortic stenosis requiring elective valve replacement in a non-
randomized, single-arm trial. The trial was designed by members of the ex-
ecutive committee, which included 1 academic principal investigator and 6
cardiac surgeons, in collaboration with the sponsor (Edwards Lifesciences
LLC). The sponsor funded the study and managed collection and monitor-
ing of the data. The ethics committee of each center approved the protocol,
and all patients gave written informed consent. Trial inclusion and exclu-
sion criteria are listed in Appendix 1. Consenting patients received the ED-
WARDS INTUITY Valve System (Model 8300A), a stented trileaflet
bovine pericardial bioprosthesis with a balloon-expandable, cloth-covered
stent frame at the inflow aspect (Figure 1).
Rapid-Deployment Aortic Valve Replacement
After standard aortotomy, the native aortic valve leaflets were excised
and calcium debridement of the annulus was performed. Three equidistant
guiding sutures were placed through the nadir of the aortic annulus and then
placed in corresponding positions through the sewing ring of the study
valve. By using the guiding sutures, the valve and attached delivery system
were lowered onto the annulus and secured into position under directThe Journal of Thoracic and Cavision. The balloon catheter was then inflated to deploy the stent frame
in a controlled fashion. Inflation pressures ranged from 3 to 5 atm depend-
ing on the size of the prosthesis. On deployment, the prosthesis was fixed in
a supra-annular position while the stent skirt frame was seated below the
annulus in a flared configuration within the left ventricular outflow tract.
Once the skirt frame was deployed, the delivery system and valve holder
were removed as a single unit, the 3 guiding sutures were tied, and the aor-
totomy was closed using standard surgical techniques. Deployment time
was defined as the time between the first suture placement on the biopros-
thesis and the end of balloon inflation. Valve implant time was defined as
the time between the first suture placement on the bioprosthesis and the
removal of the delivery system. Postoperative anticoagulant therapy was
recommended in accordance with the American College of Cardiology/
American Heart Association 2006 Guidelines for Management of Patients
with Valvular Heart Disease.10
End Points
Safety end points included valve-related mortality, thromboembolic
events, studyvalve thrombosis,major bleeding events, paravalvular leakage,
and prosthetic valve endocarditis. Definitions are included in Appendix 2.
The study protocol was guided by ISO 5840:2005 and ISO14155:2011. Per-
formance end points included device technical success, procedural success,
deployment time, implant time, changes in New York Heart Association
(NYHA) class, and echocardiographic hemodynamic performance.
Follow-up
Clinical and echocardiographic follow-up data were collected at
discharge, 3 months, and 1 year postoperatively. The following procedures
were performed at 3 months and 1 year: physical examination, assessment
of complications, coagulation profile, transthoracic echocardiography, and
blood studies. Functional assessment was performed at baseline, at
3 months, and at 1 year. Hemodynamic data were reviewed by an indepen-
dent echocardiographic core laboratory (Columbia University Medical
Center, New York, NY), and complications were adjudicated by an inde-
pendent Clinical Events Committee. Aggregate data were reviewed by an
independent Data Safety Monitoring Board.
Statistics
Continuous variables are summarized as mean and standard deviation.
Categoric variables are summarized as the number and percentage of sub-
jects in each category. Complications were summarized for the early (30
days postoperatively) and late (>30 days postoperatively) periods. Early
rates are calculated as the number of events divided by the number of sub-
jects receiving implants (as-treated analysis). Linearized rates for compli-
cations are calculated for the late period as the number of late events
divided by the number of late patient-years.RESULTS
Patient Demographics
The EDWARDS INTUITY Valve System was implanted
in 146 of 152 patients. Nonstudy valves were implanted in 6
patients (lack of valve size availability in 4 and aberrant an-
nular morphology in 2). The mean age of the 146 patients
was 75.5  6.7 years (range, 51-89 years). Patients had
a European System for Cardiac Operative Risk Evaluation
of 7.9  6.5, and 52.7% were female (Table 1).Intraoperative Findings
Overall technical success and procedural success were
achieved in 96.1% (146/152) and 97.3% (142/146) of therdiovascular Surgery c Volume 145, Number 1 111
FIGURE 1. Rapid-deployment aortic valve: EDWARDS INTUITYValve
System, Model 8300A (Edwards Lifesciences LLC, Irvine, Calif).
TABLE 2. Intraoperative data
Parameter n (%) or mean ± SD
Valve size (mm) (n ¼ 146)
19 1 (0.7%)
21 50 (34.2%)
23 52 (35.6%)
25 35 (24.0%)
27 8 (5.5%)
Procedures (n ¼ 146)
AVR only 86 (58.9%)
AVRþCABG 36 (24.7%)
AVRþother 24 (16.4%)
Surgical approach (n ¼ 146)
Full sternotomy 102 (69.9%)
Minimally invasive approach 44 (30.1%)
Upper hemisternotomy 43 (29.5%)
Right anterior minithoracotomy 1 (0.7%)
Deployment time (min) (n ¼ 133)* 9.7  4.3
Valve implant time (min) (n ¼ 145)y 11.0  6.6
Crossclamp time (min) (n ¼ 134)z 46.6 16.4
AVR only (n ¼ 80) 41.1  10.6
AVRþCABG (n ¼ 32) 60.0  19.0
AVRþother (n ¼ 22) 47.0  19.2
CPB time (min) (n ¼ 134)z 75.1  26.4
AVR only (n ¼ 80) 66.3  18.7
AVRþCABG (n ¼ 32) 95.6  30.4
AVRþother (n ¼ 22) 77.2  28.1
SD, Standard deviation; AVR, aortic valve replacement; CABG, coronary artery
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Dcases, respectively. The device was implanted through a full
sternotomy (69.9%) or a minimally invasive approach
(30.1%), which included an upper hemisternotomy in
97.7% of theminimally invasive surgery cases (Table 2). Iso-
lated AVR was performed in 58.9% of the cases, and AVR
with concomitant coronary artery bypass grafting (CABG)
(31, 32, 33) was performed in 24.7% of the cases. In
16.4% of the cases, AVR was performed concomitantly
with another procedure, such as carotid thromboendarterec-
tomy (n ¼ 2), excision of mediastinal tumor (n ¼ 1),
occlusion of atrioseptal defect (n ¼ 1), Maze procedure
(n¼ 12), septal myectomy (n¼ 2), and occlusion of foramen
ovale (n ¼ 2).bypass grafting; CPB, cardiopulmonary bypass. Deployment and valve implant times
are summarized for the successful implant. *In 13 cases, balloon inflation time was
not reported. yIn 1 case, delivery system removal time was not reported. zTechnical
success in the first attempt.
TABLE 3. Early and late complications
Parameter
Early (30 d)
(n ¼ 146)
N (%)
Late (>30 d)
(late patient-y ¼ 107.28)
N (%)Complications
At 3 months and 1 year, 133 and 96 patients had com-
pleted follow-up, respectively, with a mean follow-up of
9.8  5.1 months (n ¼ 146). All-cause and valve-related
early mortality were 2.1% (3/146) and 1.4% (2/146), re-
spectively. The specific causes of early mortality were re-
ported as sepsis (non–valve related), heart failure, and
cardiopulmonary failure. All-cause and valve-related late
mortality were 7.5% and 1.9%, respectively (Table 3).
The specific causes of late deaths were reported as respira-
tory failure (n¼ 2), infection (n ¼ 1), rupture of abdominal
aortic aneurysm (n ¼ 1), advanced metastatic cancer
(n ¼ 1), myocardial infarction (n ¼ 1), thromboembolic
event (n¼ 1) (valve related), and multisystem organ failure
(n¼ 1) (valve related). Four early (2.7%) (4/146) and 2 late
(1.9%) thromboembolic events were reported. One earlyTABLE 1. Baseline characteristics of patients (n ¼ 146)
Parameter Mean ± SD, or n (%)
Age (y) 75.5  6.7
Female 77 (52.7%)
Risk level, logistic euroSCORE I (%)* 7.9  6.5
NYHA class III or IV 68 (46.6%)
SD, Standard deviation; euroSCORE, European System for Cardiac Operative Risk
Evaluation; NYHA, New York Heart Association. *Logistic euroSCORE I data
were not available for 4 patients.
112 The Journal of Thoracic and Cardiovascular Surg(0.7%) (1/146) procedure-related reoperation for major
bleeding was reported. No cases of coronary ostial obstruc-
tion or prosthesis interference with aortotomy closure were
observed. Two early (1 mild and 1 mild/moderate) cases
of paravalvular leak (1.4%) (2/146) that remained un-
changed over 1 year were reported. In addition, 1 late mod-
erate/severe paravalvular leak (0.9%) was reported atMortality
All cause 3 (2.1%) 8 (7.5%)
Valve related 2 (1.4%) 2 (1.9%)
Thromboembolism 4 (2.7%) 2 (1.9%)
Reoperation for bleeding 1 (0.7%) 0 (0.0%)
Paravalvular leak (>1þ) 2 (1.4%) 1 (0.9%)
Explant 2 (1.4%) 2 (1.9%)
Endocarditis 0 (0.0%) 0 (0.0%)
Hemolysis 0 (0.0%) 0 (0.0%)
Structural valve deterioration 0 (0.0%) 0 (0.0%)
N represents the number of events.
ery c January 2013
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Dpostoperative day 92, which led to a reoperation with ex-
plant of the prosthetic valve. At explant, the annulus ap-
peared circumferentially irregular with a notch in the left
coronary–right coronary commissure region that corre-
sponded to the paravalvular leak observed at the 3-month
echocardiographic assessment. Two early (1.4%) (2/146)
and 2 late (1.9%) explants were reported (all were proce-
dure and valve related). The specific causes of early explant
were reported as bleeding during and after the procedure
because of aortic dissection and cardiogenic shock leading
to valve damage secondary to manual cardiopulmonary
resuscitation. The specific causes of late explants were
reported as worsening paravalvular leak from moderate to
severe and pseudoaneurysm of the left ventricular outflow
tract observed at the 3-month echocardiographic assess-
ment. At the time of explant, the patient was asymptomatic
with good valve function and absence of paravalvular leak
or insufficiency. No endocarditis, hemolysis, or structural
valve deterioration was observed.
Early permanent pacemaker implant was required in 10
patients and adjudicated as study valve related in 7 patients
(5.0%) (7/141) (Table 4). Of note, all early valve-related per-
manent pacemaker implants had preexisting conduction is-
sues. Preexisting conduction disturbances included atrial
fibrillation (n ¼ 4), atrioventricular block (I and II) (n ¼ 5),
and right or left bundle branch block (n¼ 5). Late permanent
pacemaker implant occurred in 3 cases, of which 1 (0.8%)
(1/127) was valve related. The 2 non–valve-related late cases
involved worsening of a preexisting conduction disturbance.Device Performance
Reported mean EOA was 1.7  0.2 cm2 at discharge
(n ¼ 90) and remained unchanged at 3 months (n ¼ 99)
and 1 year (n ¼ 65). Mean and peak systolic gradients
were 9.8 3.3 mm Hg and 18.7 6.5 mm Hg at discharge,
respectively (n ¼ 108). Mean and peak pressure gradients
were 8.8  3.0 mm Hg and 16.7  6.0 mm Hg at 3 months
(n ¼ 106), respectively, and decreased to 8.4  3.4 mm Hg
and 15.8  5.7 mm Hg at 1 year (n ¼ 68), respectively.
The majority of patients showed improvement (75.0%)
(99/132) or remained in the same NYHA class (22.7%) atTABLE 4. Postoperative permanent pacemaker implants
Time period Patient description
No baseline cond
disturbance n
30 d No. of patients at risk 102
Valve related 0 (0.0%)
Non–valve related 1 (1.0%)
>30 d No. of patients at risk 98
Valve related 1 (1.0%)
Non–valve related 0 (0.0%)
Patients at risk have reached the start of the interval without a permanent pacemaker impl
implant by the end of the interval divided by the number at risk at the start of the interval
baseline electrocardiogram with no other conditions checked. Patients with a baseline pac
The Journal of Thoracic and Ca3 months postoperatively, with 93.2% (123/132) of patients
in NYHA class I or II. At 1 year, patients showed continued
improvement (75.0%) (72/96) or remained the same
(21.9%), with 96.9% (93/96) of patients having class I or
II symptoms.DISCUSSION
The 1-year outcomes from a 152-patient cohort undergo-
ingAVRwith the EDWARDS INTUITYValve Systemdem-
onstrate that the valve is safe, feasible, and efficacious.
RDAVR with the EDWARDS INTUITY Valve System
yields a high technical success rate of 96.1%, with flexibility
in procedural approach ranging from full sternotomy to up-
per hemisternotomy to right anterior mini-thoracotomy.
Minimally invasive techniques offer the benefit of pain
and scar reduction, along with shorter ventilation times,
shorter intensive care unit and hospital lengths of stay, less
blood loss, and faster return to routine life activities.8,9,11
In this study, RDAVR with the EDWARDS INTUITY
Valve System facilitated minimally invasive surgical
approaches in 48.8% (42/86) of the isolated AVRs. In
2009,Gummert and colleagues12 reported, from theGerman
Database, that only 10.2% of the isolated AVRs were per-
formed using the minimally invasive approach.
Previous studies have identified prolonged crossclamp
time as a predictor of major postoperative mortality, mor-
bidity, and length of hospital stay in both low- and
high-risk patients.13,14 Salis and colleagues15 identified
prolonged crossclamp and bypass times as independent pre-
dictors of morbidity and mortality after cardiac surgery in
a cohort of more than 5000 patients. In 2 separate cohorts
totaling more than 3200 patients, Dewey and colleagues16
reported crossclamp times in the range of 86 to 88 minutes
with an early mortality rate of 5.3% in all AVRs, whereas
Chan and colleagues17 reported crossclamp times for all
AVRs ranging from 82 to 84 minutes with an early mortality
rate of 5.0%. As previously discussed, the crossclamp time
in our experience was 47  16 minutes with an early mor-
tality rate of 1.4%. In this 12-month experience, rates for
early thromboembolic events, paravalvular leak, and
permanent pacemaker implant of 2.7%, 1.4%, and 5.0%,uction
(%)
Previous conduction
disturbance n (%) All subjects n (%)
39 141
7 (17.9%) 7 (5.0%)
2 (5.1%) 3 (2.1%)
29 127
0 (0.0%) 1 (0.8%)
2 (6.9%) 2 (1.6%)
ant. Percentages are based on the number of patients with a postoperative pacemaker
. Patients with ‘‘no baseline conduction disturbances’’ are those with ‘‘sinus’’ at the
emaker or pacemaker implanted intraoperatively are not included in this analysis.
rdiovascular Surgery c Volume 145, Number 1 113
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Drespectively, compare favorably with reported range rates
for conventional AVR of 2.7% to 3.9%, 5.6% to 6%,
and 3% to 11.8%, respectively.16,18-21
Reproducible crossclamp and CPB times were demon-
strated in isolated RDAVR and complex RDAVR.We report
crossclamp times of 41  11 minutes and 60  19 minutes
for RDAVR and RDAVRþCABG, respectively. CPB times
were 66 19 minutes and 96 30 minutes for RDAVR and
RDAVR þ CABG, respectively. The EPICARD Database
reported crossclamp times of 57 and 87 minutes for isolated
AVR and AVRþCABG, respectively.22 CPB times were 76
and 113 minutes for isolated AVR and AVR þ CABG,
respectively. In a 1000-patient cohort, McClure and
colleagues23 report crossclamp times of 75  1 minutes
and 98  2 minutes for AVR and AVRþCABG, respec-
tively. CPB times for AVR and AVRþCABG were reported
as 106  2 minutes and 136  2 minutes, respectively.
Thus, when compared with conventional AVR procedural
times from the study by McClure and colleagues, mean
reductions in crossclamp time for isolated RDAVR and
RDAVR þ CABG were 45% and 39%, respectively,
whereas mean reductions in CPB times for RDAVR and
RDAVRþCABG were 38% and 29%, respectively.
The design concept of the EDWARDS INTUITY Valve
System is based on the Carpentier-Edwards Perimount
valve. To date, more than 500,000 Perimount aortic valves
have been implanted in patients.24,25 The hallmarks of the
Perimount valve include a low profile, supra-annular design,
and unique anticalcification technology. The hemodynamic
performance of the Perimount valve has been reported.2,3
The hemodynamic performance of the EDWARDS
INTUITY Valve System favorably correlates with the
hemodynamic performance reported in the literature for
Perimount valves. Dalmau and colleagues3 reported
a mean EOA and pressure gradient of 1.9  0.4 cm2 and
10.3  3.4 mm Hg at 1 year, respectively, whereas Cohen
and colleagues2 reported a mean EOA and pressure gradient
of 1.9 0.6 cm2 and 7.1 3.7mmHg at 1 year, respectively.
Furthermore, Cohen and colleagues demonstrated favorable
long-term hemodynamic performance of the Carpentier-
Edwards Perimount valves at 9 years, with a mean EOA
and mean pressure gradient of 1.5  0.6 cm2 and 10.9 
3.7 mm Hg, respectively.2
Study Limitations
This was a nonrandomized, single-arm study without
a concurrent control group. Roll-in cases were included in
these data, and a learning curve impact is not taken into ac-
count. Other important limitations may include the possibil-
ity of selection and performance biases due a nonblinded
study design, as well as attrition biases resulting from miss-
ing data points. In addition, these reported data extend up to
only 1 year, and long-term performance and complications
may differ over an extended period of time.114 The Journal of Thoracic and Cardiovascular SurgCONCLUSIONS
TheEDWARDS INTUITYValve System is safe, feasible,
and efficacious. RDAVR with the EDWARDS INTUITY
Valve System facilitates minimally invasive surgical ap-
proaches while offering reproducible reductions in cross-
clamp and bypass times, which may yield potential
benefits of shortened length of hospital stay, along with im-
provements in morbidity and mortality outcomes. Excellent
hemodynamics and low complication rates are reported.
Given the similarity in basic valve design, the long-term du-
rability and hemodynamic performance of the EDWARDS
INTUITY Valve System should be consistent with that of
the Perimount family of valves. Further evaluation,
including long-term follow-up and future studies with a pro-
spective, randomized, controlled design, is recommended
for assessment of conventional AVR and RDAVR.References
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DAPPENDIX 1. INCLUSION AND EXCLUSION
CRITERIA
TRITON trial inclusion criteria were as follows: patient
aged 18 years or more; patient who has aortic stenosis or
stenosis insufficiency of an aortic valve requiring a planned
replacement as indicated in the preoperative evaluation; pa-
tient who is scheduled to undergo planned AVR with or
without concomitant coronary bypass surgery; patient
who has signed and dated the study informed consent
form before study procedures; and patient who is geograph-
ically stable and agrees to attend follow-up assessments at
the hospital of surgical services for a maximum of 5 years.
TRITON trial exclusion criteria were as follows: patient
with pure aortic insufficiency; patient who requires emer-
gency surgery; patient with an aneurysm of the aortic root
or ascending aorta requiring surgical intervention; patient
with a left ventricular ejection fraction less than 25%; pa-
tient with a congenital bicuspid aortic valve; patient who
has had active endocarditis within 3 months before the
scheduled AVR surgery; patient with concomitant valve
(mitral, tricuspid, pulmonic) disease requiring repair with
an annuloplasty ring or replacement with a prosthesis; pa-
tient who has had prior mitral prior mitral, tricuspid, or pul-
monic valve surgery, which included implantation of
a bioprosthetic valve, mechanical valve, or annuloplasty
ring that will remain in situ; patient who has had a myocar-
dial infarction within 1 month before the scheduled AVR
surgery; patient who has a noncardiac disease limiting life
expectancy to less than 12 months; patient who previously
received an EDWARDS INTUITY (Edwards Lifesciences
LLC, Irvine, Calif) valve implant; patient who is an intrave-
nous drug abuser; patient who is female or lactating; patient
who is currently participating in another drug or device clin-
ical investigation; and patient with documented blood
diathesis.APPENDIX 2. END POINT DEFINITIONS
Embolism is defined as a free-flowing blood clot or lesion
material that is located in the systemic or pulmonary
circulation that occurs in the absence of infection afterThe Journal of Thoracic and Caimmediate perioperative period. It may be manifested as
a neurologic event or noncerebral embolic event; a noncere-
bral event is an embolus documented operatively, clinically,
or during autopsy that produces signs and symptoms due
to partial or complete obstruction of a peripheral artery.
The event excludes postoperative myocardial infarction
unless detected by operation, clinical imaging, autopsy, or
emboli due to nonthrombotic material (atherosclerosis,
myxoma).
Valve thrombosis is defined as a blood clot not associated
with infection, causing dysfunction of the heart valve sub-
stitute. Diagnosis is confirmed by echocardiography, angio-
cardiography or magnetic resonance imaging, operation,
explant, or autopsy.
Bleeding event is defined as any episode of major internal
or external bleeding that causes death, hospitalization, or
permanent injury (eg, vision loss) or necessitates transfu-
sion. Major bleeding unexpectedly associated with minor
trauma should be reported as a bleeding event, but bleeding
associated with major trauma or a major operation is con-
sidered secondary to those events and should not be re-
ported. Bleeding events are reported for all patients
regardless of whether they are taking anticoagulants or anti-
platelet drugs. Although total bleeding events must be re-
ported, bleeding events also can be reported separately for
those who are taking anticoagulants or antiplatelet agents
and those who are not.
Paravalvular leak is defined as a clinically or hemody-
namically detectable defect between the heart valve substi-
tute and the patient’s annulus.
Endocarditis is an inflammation or infection of the endo-
cardium, which is the inner lining of the heart muscle and,
most commonly, the heart valves, typically caused by bac-
terial infection but can be caused by fungus. An infection
for which no source is identified and may or may not be
associated with classic signs of endocarditis (eg, red blood
cell casts in urine, splinter hemorrhages in finger nails, roof
of mouth, lesions on retina) and may or may not be associ-
ated with a vegetation inside the atrium or on a valve. Event
must be confirmed by 2 consecutive positive blood cultures
or imaging study, explant, or autopsy.
Technical success was defined as delivery and deploy-
ment of the study valve within 2 attempts.
Procedural success was defined as technical success and
the absence of complications requiring device reoperation,
permanent pacemaker implant (with baseline sinus rhythm
and no conduction issues), or death.Discussion
Dr G. Hossein Almassi (Milwaukee, Wis). You have a high in-
cidence of primary pacemaker implantation. Is it something
related to the design of the valve or the pressure at implantation
of the valve? Do you have any insight into that?rdiovascular Surgery c Volume 145, Number 1 115
Acquired Cardiovascular Disease Kocher et al
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DDrLaufer.All patients who came out of the operating room and
had finally been implanted with a pacemaker after the operation
had a pre-existing conduction disturbance, and if you study the
published data, they report a rate of 5% to 11% of permanent pace-
maker insertion after isolated aortic valve replacement. However,
in these cases, we also had isolated aortic and as aortic valve re-
placement plus CABG. So, I would say the profile of the patient
was, as evident by the European System for Cardiac Operative
Risk Evaluation, quite high.
Dr Harald C. Eichstaedt (Oldenburg, Germany). I am the co-
author of the following report, which discusses a different type of
sutureless valve. My question is related to the incidence of throm-
boembolic events that you have shown. Four patients had a stroke
in the early postoperative period and two later on. I would like to
ask you to explain your postoperative anticoagulation regimen.
Dr Laufer. The postoperative anticoagulation regimen was
low-molecular-weight heparin until the patients were switched
to warfarin (Coumadin), if there were no contraindications.
Dr Christopher Young (London, United Kingdom). I would
like to ask you briefly what you think the learning curve is for
the insertion of this.
Dr Laufer. This is a very good question. The learning curve in
this situation for 17 surgeons was there, because it was a com-
pletely new product. It is important to note that we photographed
the implantation procedure in the first cases. We evaluated the116 The Journal of Thoracic and Cardiovascular Surginflated stent below the valve with either a dental mirror or, in
some cases, with an endoscope to learn more about how the valve
sits in the outflow tract. The isolated aortic cases can be done with
a crossclamp time of 20 to 30 minutes.
Dr Young. Studying all those subgroups of ministernotomy, full
sternotomy, AVRplus, andAVR on its own, do you have a sense for
which group this had the largest impact in, who goes to intensive
care unit quicker, who goes home earliest?Where is the big effect?
Dr Laufer. It is too early to determine which group is the one
that profits most from this new valve, but basically all patients
will benefit, because the procedure time is substantially shorter,
the crossclamp time is substantially shorter. We do not have pled-
gets. I could not show, because the time was too short, the outflow
aspect from the ventricular side. We have no pledgets below the
valve. Thus, the hemodynamics are really superior. Also, com-
pared with a standard Magna valve, it is very easy to close the aor-
totomy, because the valve is hooked up below the annulus and not
with stitches at the annulus.
DrCharles R. Bridges (Charlotte, NC).Your mean crossclamp
time was 41 minutes. I was wondering whether during the course
of the study you noticed a decline in the crossclamp time so we
could have a better idea of the crossclamp time one could expect
after the learning curve.
Dr Laufer. A very good question, but we did not study these
statistics.ery c January 2013
